These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23019714)

  • 21. HDL: who needs it?
    Wierzbicki AS
    Int J Clin Pract; 2011 Nov; 65(11):1111-3. PubMed ID: 21995687
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; Shamp TR
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New focus on raising HDL "good" cholesterol. But the value of this is not entirely clear.
    Duke Med Health News; 2012 Feb; 18(2):3. PubMed ID: 22397008
    [No Abstract]   [Full Text] [Related]  

  • 26. A case for immediate-release niacin.
    Bassan M
    Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
    Florentin M; Liberopoulos EN; Kei A; Mikhailidis DP; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):385-400. PubMed ID: 21314635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 29. On call. In your January 2007 article on cholesterol, you said that no-flush niacin does not lower cholesterol levels. But my problem is low HDL cholesterol. Will no-flush niacin help my HDL even if it won't lower my LDL cholesterol?
    Simon HB
    Harv Mens Health Watch; 2007 Jun; 11(11):7-8. PubMed ID: 17644843
    [No Abstract]   [Full Text] [Related]  

  • 30. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apple pectin for the reduction of niacin-induced flushing.
    Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K
    J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Flush-free niacin": dietary supplement may be "benefit-free".
    Norris RB
    Prev Cardiol; 2006; 9(1):64-5. PubMed ID: 16407706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What is the future for niacin after the AIM-HIGH study?].
    Cybulska B; Kłosiewicz Latoszek L
    Kardiol Pol; 2012; 70(3):315-6. PubMed ID: 22430425
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial puts niacin--and cholesterol dogma--in the line of fire.
    Dolgin E
    Nat Med; 2011 Jul; 17(7):756. PubMed ID: 21738133
    [No Abstract]   [Full Text] [Related]  

  • 36. [Nicotinic acid and the derivative].
    Ogaki S; Matsushima T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract]   [Full Text] [Related]  

  • 37. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of simvastatin-niacin and antioxidant therapy on HDL.
    Drown DJ
    Prog Cardiovasc Nurs; 2002; 17(2):102-3. PubMed ID: 11986546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.